Qupet Cream

Impetigo

Topical use only Apply a thin layer topically to affected area Wash hands prior to application if the hands are not the area for treatment Do not swallow ozenoxacin or use it in the eyes, mouth, lips, inside the nose, or inside the female genital area Treated area may be covered by a sterile bandage or gauze dressing

Impetigo Indicated for impetigo due to Staphylococcus aureus (S. aureus) or Streptococcus pyogenes (S. pyogenes) in adults and children aged >2 months Apply a thin layer topically to affected area q12hr for 5 days Affected area may be up to 100 cm² in adults and adolescents aged >12 years

Impetigo Indicated for impetigo due to Staphylococcus aureus (S. aureus) or Streptococcus pyogenes (S. pyogenes) in adult and children ?2 months See also Administration <2 months: Safety and efficacy not established 2 months to <12 years Apply a thin layer topically to affected area q12hr for 5 days Affected area may be up to 2% of the total body surface area and not exceeding 100 cm² >12 years Apply a thin layer topically to affected area q12hr for 5 days Affected area may be up to 100 cm² in adults and adolescents aged >12 years

Quinolone antimicrobial drug; it inhibits bacterial DNA replication enzymes, DNA gyrase A, and topoisomerase IV Ozenoxacin has been shown to be bactericidal against S. aureus (including methicillin-resistant isolates) and S. pyogenes organisms

Prolonged use of ozenoxacin may result in overgrowth of nonsusceptible bacteria and fungi; if such infections occur, discontinue use and institute alternative therapy Antagonism interactions with ozenoxacin were observed with ciprofloxacin against S. aureus

Frequency Not Defined Rosacea Seborrheic dermatitis

Pregnancy Data are not available on the use of ozenoxacin in pregnant women Systemic absorption of ozenoxacin in humans is negligible following topical administration of ozenoxacin; owing to the negligible systemic exposure, it is not expected that maternal use of ozenoxacin will result in fetal exposure to the drug Lactation No data are available regarding the presence of ozenoxacin in human milk, and the effects of ozenoxacin on the breastfed infant or on milk production Breastfeeding is not expected to result in exposure of the child to ozenoxacin due to the negligible systemic absorption of ozenoxacin in humans following topical administration of ozenoxacin